Oncology News | pharmaphorum

News

Astellas taps GO's glycoprotein platform with $783.5m deal

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targ

News

SEC accuses former AstraZeneca exec of insider trading

The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights to Daiichi Sankyo's breast

News

Targeting COVID-19 and cancer with immunotherapy advancements

RhoVac pummelled as lead cancer vaccine fails study

Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate

News

BMS' Opdivo gets late-stage oesophageal cancer nod from FDA

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb's PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held b

News

Mirati heads for FDA verdict on KRAS drug with new data

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen.

News

Roche trumpets new glofitamab data in lymphoma at ASCO

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.

Astellas taps GO's glycoprotein platform with $783.5m deal

SEC accuses former AstraZeneca exec of insider trading

RhoVac pummelled as lead cancer vaccine fails study

BMS' Opdivo gets late-stage oesophageal cancer nod from FDA

Mirati heads for FDA verdict on KRAS drug with new data

Roche trumpets new glofitamab data in lymphoma at ASCO

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks